{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:43:11Z","timestamp":1792629791863,"version":"4.5.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T00:00:00Z","timestamp":1720483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004622","name":"Dutch Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalofhospitalinfection.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hospital Infection"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jhin.2024.06.009","type":"journal-article","created":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T07:22:43Z","timestamp":1720941763000},"page":"56-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["The CATERPILLAR study: an assessor-blinded randomized controlled trial comparing a taurolidine\u2013citrate\u2013heparin lock solution to a heparin-only lock solution for the prevention of central-line-associated bloodstream infections in paediatric oncology patients"],"prefix":"10.1016","volume":"152","author":[{"given":"C.H.","family":"van den Bosch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.G.T.","family":"Loeffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.F.W.","family":"van der Steeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"van der Bruggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.N.J.","family":"Frakking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fiocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.P.","family":"van de Ven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.H.W.A.","family":"Wijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.D.","family":"van de Wetering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhin.2024.06.009_bib1","doi-asserted-by":"crossref","first-page":"e1331","DOI":"10.1542\/peds.2015-1507","article-title":"Complications of central venous access devices: a systematic review","volume":"136","author":"Ullman","year":"2015","journal-title":"Pediatrics"},{"issue":"6","key":"10.1016\/j.jhin.2024.06.009_bib2","first-page":"CD008975","article-title":"Antibiotic and other lock treatments for tunnelled central venous catheter-related infections in children with cancer","author":"Schoot","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhin.2024.06.009_bib3","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1016\/j.jpedsurg.2018.10.054","article-title":"Incidence, severity and outcome of central line related complications in pediatric oncology patients; a single center study","volume":"54","author":"van den Bosch","year":"2019","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.jhin.2024.06.009_bib4","first-page":"347","article-title":"Is taurolidine-citrate an effective and cost-effective hemodialysis catheter lock solution? A systematic review and cost-effectiveness analysis","volume":"30","author":"Kavosi","year":"2016","journal-title":"Med J Islam Repub Iran"},{"key":"10.1016\/j.jhin.2024.06.009_bib5","doi-asserted-by":"crossref","first-page":"453","DOI":"10.5301\/jva.5000576","article-title":"Evidence-based criteria for the choice and the clinical use of the most appropriate lock solutions for central venous catheters (excluding dialysis catheters): a GAVeCeLT consensus","volume":"17","author":"Pittiruti","year":"2016","journal-title":"J\u00a0Vasc Access"},{"key":"10.1016\/j.jhin.2024.06.009_bib6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jhin.2021.10.022","article-title":"The efficacy of taurolidine containing lock solutions for the prevention of central-venous-catheter-related bloodstream infections: a systematic review and meta-analysis","volume":"123","author":"van den Bosch","year":"2022","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.jhin.2024.06.009_bib7","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.clnu.2012.11.014","article-title":"Absence of microbial adaptation to taurolidine in patients on home parenteral nutrition who develop catheter related bloodstream infections and use taurolidine locks","volume":"32","author":"Olthof","year":"2013","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jhin.2024.06.009_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0008927","article-title":"Taurolidine antiadhesive properties on interaction with E.\u00a0coli; its transformation in biological environment and interaction with bacteria cell wall","volume":"5","author":"Caruso","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.jhin.2024.06.009_bib9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2672.1987.tb04926.x","article-title":"Reduced adherence of micro-organisms to human mucosal epithelial cells following treatment with Taurolin, a novel antimicrobial agent","volume":"62","author":"Gorman","year":"1987","journal-title":"J\u00a0Appl Bacteriol"},{"key":"10.1016\/j.jhin.2024.06.009_bib10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clnu.2014.04.023","article-title":"Microbiocidal effects of various taurolidine containing catheter lock solutions","volume":"34","author":"Olthof","year":"2015","journal-title":"Clin Nutr"},{"key":"10.1016\/j.jhin.2024.06.009_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1472-765X.1987.tb01593.x","article-title":"Electron and light microscopic observations of bacterial cell surface effects due to taurolidine treatment","volume":"4","author":"Gorman","year":"1987","journal-title":"Appl Microbiol"},{"key":"10.1016\/j.jhin.2024.06.009_bib12","series-title":"GRADE handbook for grading quality of evidence and strength of recommendations","year":"2013"},{"key":"10.1016\/j.jhin.2024.06.009_bib13","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jhin.2012.01.003","article-title":"Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies","volume":"80","author":"D\u00fcmichen","year":"2012","journal-title":"J\u00a0Hosp Infect"},{"key":"10.1016\/j.jhin.2024.06.009_bib14","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1002\/pbc.24482","article-title":"Central venous catheters and catheter locks in children with cancer: a prospective randomized trial of taurolidine versus heparin","volume":"60","author":"Handrup","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jhin.2024.06.009_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4103\/0189-6725.132806","article-title":"Complications of total implantable access ports and efficacy of taurolidine-citrate lock solution against catheter-related infections","volume":"11","author":"Ince","year":"2014","journal-title":"Afr J Paediatr Surg"},{"key":"10.1016\/j.jhin.2024.06.009_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-2334-8-102","article-title":"Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients","volume":"8","author":"Simon","year":"2008","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jhin.2024.06.009_bib17","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1097\/INF.0000000000002191","article-title":"Taurolidine-citrate line locks prevent recurrent central line associated bloodstream infection in pediatric patients","volume":"38","author":"Clark","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jhin.2024.06.009_bib18","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/jpc.14506","article-title":"Taurolidine-citrate lock solution for the prevention of central line-associated bloodstream infection in paediatric haematology\u2013oncology and gastrointestinal failure patients with high baseline central-line associated bloodstream infection rates","volume":"56","author":"Chong","year":"2020","journal-title":"J\u00a0Paediatr Child Health"},{"key":"10.1016\/j.jhin.2024.06.009_bib19","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-069760","article-title":"CATERPILLAR-study protocol: an assessor-blinded randomised controlled trial comparing taurolidine\u2013citrate\u2013heparin to heparin-only lock solutions for the prevention of central line-associated bloodstream infections in paediatric oncology patients","volume":"13","author":"van den Bosch","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhin.2024.06.009_bib20","first-page":"1","year":"2023","journal-title":"National Healthcare Safety Network"}],"container-title":["Journal of Hospital Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195670124002287?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0195670124002287?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T15:07:39Z","timestamp":1736780859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0195670124002287"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":20,"alternative-id":["S0195670124002287"],"URL":"https:\/\/doi.org\/10.1016\/j.jhin.2024.06.009","relation":{},"ISSN":["0195-6701"],"issn-type":[{"value":"0195-6701","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The CATERPILLAR study: an assessor-blinded randomized controlled trial comparing a taurolidine\u2013citrate\u2013heparin lock solution to a heparin-only lock solution for the prevention of central-line-associated bloodstream infections in paediatric oncology patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Hospital Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhin.2024.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The Healthcare Infection Society.","name":"copyright","label":"Copyright"}]}}